English
Русский
The 21st century is not only a time of progress in innovative technologies and artificial intelligence, but also a time of global downgrade and early development of serious health disorders, especially oncological and cardiovascular diseases. Currently, various cerebrovascular disorders have become widespread, which are the main limitation factors in rational therapy. This is due to the complications of primary diagnosis of the disease and its confirmation, as well as the problems in the application of early neuroprotection and rehabilitation. The aim of the study. The research of new compound’s neuroprotective properties: the dipotassium salt of N-(3-hydroxybenzoyl)taurine, which is a derivate of hydroxybenzoic acid, by the different types of vascular (blood circulation) disorders in the brain. Materials and methods. The examination of the dipotassium salt of N-(3-hydroxybenzoyl)taurine, as a derivate of hydroxybenzoic acid. Establishing the neurological status using the Combs & D`Alecy scale and the Gracia scale. Results. The research results let to suggest the cerebroprotective properties of a new hydroxybenzoic acid derivate, which demonstrates potential comparable to Citicoline, Nicergoline, and Acetylsalicylic acid in decrease the damage of the neuropsychiatric consequences of ischemic injury. The examine compound, like these other drugs, exhibits properties aimed at stabilizing cerebral circulation and reducing the manifestations of endothelial dysfunction. Conclusions. According to study findings the dipotassium salt of N-(3-hydroxybenzoyl)taurine exhibits cerebroprotective effects in various cerebrovascular disorders.
1. Zhivolupov S.A., Samartsev I.N. Timely diagnostics and rational therapy of cerebrovascular diseases within the framework of a modern strategy of primary and secondary stroke prevention. Nervous diseases scientific journal on the topic: Clinical medicine: electronic version. 2022. No. 2. P. 28 – 37. URL: https://cyberleninka.ru/ (date of access: 08.01.2024)
2. Gureeva I.L., Gomzyakova N.A., Sel'kin M.D., Isaeva E.R., Golikov K.V. Neuropsychological changes in patients with acute cerebrovascular accident. Psychology. Psychophysiology. scientific journal on the topic: Biological sciences, Psychological sciences: electronic version. 2017. No. 4. P. 28 – 36. URL: https://cyberleninka.ru/ (date ofaccess: 08.01.2024)
3. Wagle K.C., Ivan C.S. Cerebrovascular Disease. Family Medicine. Springer. 2022. P. 905 – 922, DOI: 10.1007/978-3-030-54441-6
4. Putilina M.V. Hierarchy of pathogenetic mechanisms of chronic cerebral circulatory insufficiency and therapeutic strategies for neuroprotection. Medical Council: electronic version. 2023. No. 3. P. 17 – 22 URL: https://cyberleninka.ru/ (date ofaccess: 01.08.2024)
5. Winstein C.J., Stein J., Arena R., Bates B., Cherney L.R., Cramer S.C., Deruyter F., Eng J.J., Fisher B., Harvey R.L., Lang C.E., MacKay-Lyons M., Ottenbacher K.J., Pugh S., Reeves M.J., Richards L.G., Stiers W., Zorowitz, R.D. Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association. American Stroke Association. Guidelines for Adult Stroke Rehabilitation and Recovery. Stroke. 2016. Vol. 47. No. 6. P. 98 – 69. DOI: 10.1161/STR.00000000000000098.
6. Kosivtsova O.V. Management of patients in the recovery period of stroke. Neurology, neuropsychiatry, psychosomatics. 2014. Vol. 6. No. 4. P. 101 – 105. DOI: 10.14412/2074-2711-2014-4-101-105
7. Laguta P.S. Acetylsalicylic acid in primary and secondary prevention of stroke. Atherothrombosis. 2017. Vol. 13. No. 1. P. 54 – 66. DOI: 10.21518/2307-1109-2017-1-54-66
8. Machinsky P.A., Plotnikova N.A., Ulyankin V.E., et al. Comparative characteristics of the incidence rates of ischemic and hemorrhagic stroke in Russia. News of higher educational institutions. Volga region. Medical sciences. 2019. Vol. 50. No. 2. P. 112 – 132. DOI: 10.21685/2072-3032-2019-2-11
9. Grigoriev E.K. Rehabilitation of patients after stroke. Handbook of a general practitioner. 2020. No. 1-2. P. 4 – 16. DOI: 10.33920/med-10-2001-01
10. Prokaeva T.A., Zhigaev G.F., Prokaev E.M., Ryabov M.P., Nikolaev A.S. Medical and economic assessment of inpatient care for stroke (literature review). Acta Biomedica Scientifica. 2015. No. 2. P. 122 – 125.
11. Panchenko E.P. Modern concepts of the place of acetylsalicylic acid in the treatment of patients with various manifestations of atherothrombosis. Atherothrombosis. 2021. No. 1. P. 89 – 105. DOI: https://doi.org/10.21518/2307-1109-2021-11-1-89-105
12. Brel A.K., Atapina A.N., Budaeva Yu.N., Lisina S.V., Tsaruk S.S., Kurkin D.V., Tyurenkov I.N. Synthesis, antiplatelet and antithrombotic activities of new derivatives of hydroxybenzoic acids with a taurine fragment. Pharmacy and Pharmacology. 2021. Vol. 9. No. 3. P. 222 – 234. DOI: 10.19163/2307-9266-2021-9-3-222-234
13. Brel A.K., Tyurenkov I.N., Lisina S.V., Volotova E.V., Popov S.S., Verkholyak D.V. N-(acetylsalicyloyl)pyrazole with a cerebroprotective effect in cerebral circulatory insufficiency. Patent for invention RU 2632005 C1, 02.10.2017. Application No. 2016139886 dated 10.10.2016.
14. Volotova E.V., Brel A.K., Verkholyak D.V. Atapina N.V., Pustynnikov V.E., Fomichev E.A. Cerebroprotective properties of hydroxybenzoic acid amide derivatives. Medicinal Bulletin. 2022. Vol. 23. No. 2. P. 32 – 39.
15. Schaffer S., Kim H.W. Effects and Mechanisms of Taurine as a Therapeutic Agent. Biomol Ther (Seoul). 2018. Vol. 26. No. 3. P. 225 – 241. doi: 10.4062/biomolther.2017.251
16. Daineko A.S., Shmonon A.A., Shumeeva A.V., Kovalenko E.A., Melnikova E.V., Vlasov T.D. Methods for assessing neurological deficit in rats after 30-minute focal cerebral ischemia in the early and late stages of the post-ischemic period. Regional blood circulation and microcirculation. 2014. Vol. 13. No. 1. P. 68 – 78. DOI: https://doi.org/10.24884/1682-6655-2014-13-1-68-78
17. Bakulin D.A., Kurkin D.V., Volotova E.V., Logvinova E.O., Avdienko K.A., Tyurenkov I.N. Psychoneurological disorders in animals with cerebral ischemia against the background of diabetes mellitus and their correction by a new GPR119 agonist and its combinations with metformin and citicoline. Pathological physiology and experimental therapy. 2019. Vol. 63. No. 31. P. 96 – 104. DOI: https://doi.org/10.25557/0031-2991.2019.03.96-104
18. Tyurenkov I.N., Kurkin D.V., Bakulin D.A., Volotova, E.V. Study of the neuroprotective effect of a new glutamic acid derivative, neuroglutam, in focal cerebral ischemia in rats. Experimental and Clinical Pharmacology. 2014. Vol. 77. No. 91. P. 8 – 12.
19. Kurkin D.V., Bakulin D.A., Morkovin E.I. Kalatanova A.V., Makarenko I.E., Dorotenko A.R., Ko-valev N.S., Dubrovina, Marina A., Verkholyak D.V., Abrosimova E.E., Smirnov A.V., Shmidt M.V., Tyurenkov I.N. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PLoS One. 2021. Vol. 16. No. 7. R. 1 – 23 DOI: https://doi.org/10.1371/journal.pone.0254493
20. Pustynnikov V.E., Tsaruk S.S., Fomichev E.A., Miloserdova E.A., Kurkin D.V., Bakulin D.A., Andriashvili T.M., Sokolova A.A., Atapina N.V., Brel A.K., Budaeva Yu.N., Tyurenkov I.N. Effect of a new derivative of salicylic acid – dipotassium salt of N-(3-hydroxybenzoyl)taurine – on neurological deficit, hemostasis and functional activity of cerebral vessels under conditions of experimental cerebrovascular accident. Siberian Scientific Medical Journal. 2022. Vol. 42. No. 5. P. 52 – 60. DOI: https://doi.org/10.18699/SSMJ20220507
21. Samorodov A.V. Development of a new platelet GP IIb-IIIa receptor blocker among xanthine derivatives: Abstract of a Doctor of Medicine Dissertation. Kazan State Medical University. Kazan; 2018. 40 p.
22. Zang G., Fang L., Chen L., Wang C. Ameliorative effect of nicergoline on cognitive function through the PI3K/AKT signaling pathway in mouse models of Alzheimer's disease. Mol Med Rep. 2018. Vol. 17. No. 5. P. 7293 – 7300. DOI: https://10.3892/mmr.2018.8786
23. Atapina N.V. Antiplatelet, antithrombotic, and cerebroprotective activity of new derivatives of hydroxybenzoic acids: Diss. … Cand. of Pharmaceutical Sciences. Volgograd State Medical University. Volgograd; 2022. 41 p.
24. Bohlen M., Cameron A., Metten P., Crabbe J.C., Wahlsten D. Calibration of rotational acceleration for the rotarod test of rodent motor coordination. J. Neurosci. Methods. 2009. Vol. 178. No. 1. P. 10 – 14. DOI: https://doi.org/10.1016/j.jneumeth.2008.11.001.
25. Combs D.J., D'Alecy L.G. Motor performance in rats exposed to severe forebrain ischemia: effect of fasting and 1,3-butanediol. Stroke. 1987. Vol. 18. No. 2. P. 503 – 511.
26. Pokrovskaya T.G. The role of pharmacological correction of the L-arginine/no metabolic pathway in modeling nitric oxide deficiency. Kuban Scientific Medical Bulletin. 2008. Vol. 3. No. 4. P. 129 – 132.
2. Gureeva I.L., Gomzyakova N.A., Sel'kin M.D., Isaeva E.R., Golikov K.V. Neuropsychological changes in patients with acute cerebrovascular accident. Psychology. Psychophysiology. scientific journal on the topic: Biological sciences, Psychological sciences: electronic version. 2017. No. 4. P. 28 – 36. URL: https://cyberleninka.ru/ (date ofaccess: 08.01.2024)
3. Wagle K.C., Ivan C.S. Cerebrovascular Disease. Family Medicine. Springer. 2022. P. 905 – 922, DOI: 10.1007/978-3-030-54441-6
4. Putilina M.V. Hierarchy of pathogenetic mechanisms of chronic cerebral circulatory insufficiency and therapeutic strategies for neuroprotection. Medical Council: electronic version. 2023. No. 3. P. 17 – 22 URL: https://cyberleninka.ru/ (date ofaccess: 01.08.2024)
5. Winstein C.J., Stein J., Arena R., Bates B., Cherney L.R., Cramer S.C., Deruyter F., Eng J.J., Fisher B., Harvey R.L., Lang C.E., MacKay-Lyons M., Ottenbacher K.J., Pugh S., Reeves M.J., Richards L.G., Stiers W., Zorowitz, R.D. Guidelines for Adult Stroke Rehabilitation and Recovery: A Guideline for Healthcare Professionals From the American Heart Association. American Stroke Association. Guidelines for Adult Stroke Rehabilitation and Recovery. Stroke. 2016. Vol. 47. No. 6. P. 98 – 69. DOI: 10.1161/STR.00000000000000098.
6. Kosivtsova O.V. Management of patients in the recovery period of stroke. Neurology, neuropsychiatry, psychosomatics. 2014. Vol. 6. No. 4. P. 101 – 105. DOI: 10.14412/2074-2711-2014-4-101-105
7. Laguta P.S. Acetylsalicylic acid in primary and secondary prevention of stroke. Atherothrombosis. 2017. Vol. 13. No. 1. P. 54 – 66. DOI: 10.21518/2307-1109-2017-1-54-66
8. Machinsky P.A., Plotnikova N.A., Ulyankin V.E., et al. Comparative characteristics of the incidence rates of ischemic and hemorrhagic stroke in Russia. News of higher educational institutions. Volga region. Medical sciences. 2019. Vol. 50. No. 2. P. 112 – 132. DOI: 10.21685/2072-3032-2019-2-11
9. Grigoriev E.K. Rehabilitation of patients after stroke. Handbook of a general practitioner. 2020. No. 1-2. P. 4 – 16. DOI: 10.33920/med-10-2001-01
10. Prokaeva T.A., Zhigaev G.F., Prokaev E.M., Ryabov M.P., Nikolaev A.S. Medical and economic assessment of inpatient care for stroke (literature review). Acta Biomedica Scientifica. 2015. No. 2. P. 122 – 125.
11. Panchenko E.P. Modern concepts of the place of acetylsalicylic acid in the treatment of patients with various manifestations of atherothrombosis. Atherothrombosis. 2021. No. 1. P. 89 – 105. DOI: https://doi.org/10.21518/2307-1109-2021-11-1-89-105
12. Brel A.K., Atapina A.N., Budaeva Yu.N., Lisina S.V., Tsaruk S.S., Kurkin D.V., Tyurenkov I.N. Synthesis, antiplatelet and antithrombotic activities of new derivatives of hydroxybenzoic acids with a taurine fragment. Pharmacy and Pharmacology. 2021. Vol. 9. No. 3. P. 222 – 234. DOI: 10.19163/2307-9266-2021-9-3-222-234
13. Brel A.K., Tyurenkov I.N., Lisina S.V., Volotova E.V., Popov S.S., Verkholyak D.V. N-(acetylsalicyloyl)pyrazole with a cerebroprotective effect in cerebral circulatory insufficiency. Patent for invention RU 2632005 C1, 02.10.2017. Application No. 2016139886 dated 10.10.2016.
14. Volotova E.V., Brel A.K., Verkholyak D.V. Atapina N.V., Pustynnikov V.E., Fomichev E.A. Cerebroprotective properties of hydroxybenzoic acid amide derivatives. Medicinal Bulletin. 2022. Vol. 23. No. 2. P. 32 – 39.
15. Schaffer S., Kim H.W. Effects and Mechanisms of Taurine as a Therapeutic Agent. Biomol Ther (Seoul). 2018. Vol. 26. No. 3. P. 225 – 241. doi: 10.4062/biomolther.2017.251
16. Daineko A.S., Shmonon A.A., Shumeeva A.V., Kovalenko E.A., Melnikova E.V., Vlasov T.D. Methods for assessing neurological deficit in rats after 30-minute focal cerebral ischemia in the early and late stages of the post-ischemic period. Regional blood circulation and microcirculation. 2014. Vol. 13. No. 1. P. 68 – 78. DOI: https://doi.org/10.24884/1682-6655-2014-13-1-68-78
17. Bakulin D.A., Kurkin D.V., Volotova E.V., Logvinova E.O., Avdienko K.A., Tyurenkov I.N. Psychoneurological disorders in animals with cerebral ischemia against the background of diabetes mellitus and their correction by a new GPR119 agonist and its combinations with metformin and citicoline. Pathological physiology and experimental therapy. 2019. Vol. 63. No. 31. P. 96 – 104. DOI: https://doi.org/10.25557/0031-2991.2019.03.96-104
18. Tyurenkov I.N., Kurkin D.V., Bakulin D.A., Volotova, E.V. Study of the neuroprotective effect of a new glutamic acid derivative, neuroglutam, in focal cerebral ischemia in rats. Experimental and Clinical Pharmacology. 2014. Vol. 77. No. 91. P. 8 – 12.
19. Kurkin D.V., Bakulin D.A., Morkovin E.I. Kalatanova A.V., Makarenko I.E., Dorotenko A.R., Ko-valev N.S., Dubrovina, Marina A., Verkholyak D.V., Abrosimova E.E., Smirnov A.V., Shmidt M.V., Tyurenkov I.N. Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats. PLoS One. 2021. Vol. 16. No. 7. R. 1 – 23 DOI: https://doi.org/10.1371/journal.pone.0254493
20. Pustynnikov V.E., Tsaruk S.S., Fomichev E.A., Miloserdova E.A., Kurkin D.V., Bakulin D.A., Andriashvili T.M., Sokolova A.A., Atapina N.V., Brel A.K., Budaeva Yu.N., Tyurenkov I.N. Effect of a new derivative of salicylic acid – dipotassium salt of N-(3-hydroxybenzoyl)taurine – on neurological deficit, hemostasis and functional activity of cerebral vessels under conditions of experimental cerebrovascular accident. Siberian Scientific Medical Journal. 2022. Vol. 42. No. 5. P. 52 – 60. DOI: https://doi.org/10.18699/SSMJ20220507
21. Samorodov A.V. Development of a new platelet GP IIb-IIIa receptor blocker among xanthine derivatives: Abstract of a Doctor of Medicine Dissertation. Kazan State Medical University. Kazan; 2018. 40 p.
22. Zang G., Fang L., Chen L., Wang C. Ameliorative effect of nicergoline on cognitive function through the PI3K/AKT signaling pathway in mouse models of Alzheimer's disease. Mol Med Rep. 2018. Vol. 17. No. 5. P. 7293 – 7300. DOI: https://10.3892/mmr.2018.8786
23. Atapina N.V. Antiplatelet, antithrombotic, and cerebroprotective activity of new derivatives of hydroxybenzoic acids: Diss. … Cand. of Pharmaceutical Sciences. Volgograd State Medical University. Volgograd; 2022. 41 p.
24. Bohlen M., Cameron A., Metten P., Crabbe J.C., Wahlsten D. Calibration of rotational acceleration for the rotarod test of rodent motor coordination. J. Neurosci. Methods. 2009. Vol. 178. No. 1. P. 10 – 14. DOI: https://doi.org/10.1016/j.jneumeth.2008.11.001.
25. Combs D.J., D'Alecy L.G. Motor performance in rats exposed to severe forebrain ischemia: effect of fasting and 1,3-butanediol. Stroke. 1987. Vol. 18. No. 2. P. 503 – 511.
26. Pokrovskaya T.G. The role of pharmacological correction of the L-arginine/no metabolic pathway in modeling nitric oxide deficiency. Kuban Scientific Medical Bulletin. 2008. Vol. 3. No. 4. P. 129 – 132.
Atapina N.V., Pustynnikov V.E., Bakulin D.A., Kurkin D.V., Budaeva Yu.N., Brel A.K., Sidorenko P.V., Gorbunova Yu.V. Study of the cerebroprotective effect of a new derivative of hydroxybenzoic acid – the dikali salt N–(3-hydroxybenzoyl)taurine in various disorders of cerebral circulation. Chemical Bulletin. 2025. 8 (4). 3. https://doi.org/10.58224/2619-0575-2025-8-4-3